Janney Montgomery Scott LLC Grows Stake in Moderna, Inc. (NASDAQ:MRNA)

Janney Montgomery Scott LLC raised its stake in Moderna, Inc. (NASDAQ:MRNA) by 37.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,825 shares of the company’s stock after acquiring an additional 3,744 shares during the period. Janney Montgomery Scott LLC’s holdings in Moderna were worth $392,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Norges Bank bought a new position in Moderna in the fourth quarter valued at about $163,833,000. Voloridge Investment Management LLC grew its holdings in Moderna by 335.6% during the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company’s stock valued at $107,727,000 after buying an additional 1,996,003 shares in the last quarter. FMR LLC grew its holdings in Moderna by 7.4% during the 4th quarter. FMR LLC now owns 18,664,634 shares of the company’s stock valued at $776,075,000 after buying an additional 1,282,469 shares in the last quarter. Pictet Asset Management Holding SA grew its holdings in Moderna by 170.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company’s stock valued at $73,447,000 after buying an additional 1,113,455 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Moderna by 24.3% in the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company’s stock valued at $208,169,000 after purchasing an additional 979,858 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Analyst Ratings Changes

MRNA has been the subject of several analyst reports. Evercore ISI lowered their price objective on Moderna from $50.00 to $32.00 and set an “in-line” rating for the company in a research note on Friday, May 2nd. Citigroup began coverage on Moderna in a research report on Thursday, March 13th. They set a “neutral” rating and a $40.00 target price for the company. UBS Group reduced their price target on Moderna from $78.00 to $70.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. William Blair reissued a “market perform” rating on shares of Moderna in a research report on Monday, June 2nd. Finally, Morgan Stanley decreased their price target on Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 9th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and an average target price of $46.61.

Moderna Stock Up 0.6%

Shares of MRNA opened at $30.47 on Friday. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $129.39. The company has a market capitalization of $11.78 billion, a price-to-earnings ratio of -3.49 and a beta of 1.84. The stock’s 50-day moving average price is $26.72 and its 200-day moving average price is $31.45.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping analysts’ consensus estimates of ($2.92) by $0.40. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. The firm had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. During the same quarter in the prior year, the business earned ($3.07) earnings per share. The company’s revenue was down 35.3% compared to the same quarter last year. As a group, equities analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.